Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Vaibhav Sahai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1892-1548; OpenAlex author ID A5076767039; NIH RePORTER profile ID 12277635. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 3, last author 2)
Trials
3 (principal investigator on 3)
Grants
1
Labs led
1
Collaborators
181
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 6 papers · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper, 2 trials, 1 grant · 2024: 6 papers, 1 trial · 2025: 4 papers · 2026: 5 papers

Papers 41

  1. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  2. Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer. Co-author DOI 10.1038/s43018-026-01158-7↗
  3. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  4. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.21203/rs.3.rs-8545050/v1↗
  5. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.64898/2026.01.06.26343539↗
  6. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  7. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  8. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08917-z↗
  9. Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-24-0210↗
  10. Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer. Last author DOI 10.1001/jamanetworkopen.2024.40047↗
  11. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreat… Co-author DOI 10.1016/j.ejca.2024.113950↗
  12. Are We There Yet? - Alternating Chemotherapy Regimens in Pancreatic Cancer. Co-author DOI 10.1056/evide2300341↗
  13. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  14. Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. Co-author DOI 10.1172/jci.insight.168824↗
  15. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. Co-author DOI 10.3390/ijms25052953↗
  16. Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2023.101266↗
  17. Retrospective Cohort Analysis of Aspirin Use and Venous Thromboembolism in Patients with Pancreatic Cancer and an Indwelling Central Venous Catheter. Co-author DOI 10.1055/s-0042-1747685↗
  18. Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/biomedicines10010146↗
  19. Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer. Co-author DOI 10.3390/ijms23147852↗
  20. Immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26312↗
  21. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Last author DOI 10.1080/14728214.2021.1905795↗
  22. Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer Co-author DOI 10.1101/2021.03.28.437388↗
  23. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  24. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resec… First author DOI 10.1016/j.ijrobp.2019.08.057↗
  25. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  26. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Co-author DOI 10.1038/s42255-020-0226-5↗
  27. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  28. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  29. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  30. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  31. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Co-author DOI 10.1089/pancan.2019.0012↗
  32. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic C… Co-author DOI 10.1200/jco.19.00730↗
  33. Profiling Heterogeneous Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC Carpet Chip. Co-author DOI 10.1002/adbi.201800228↗
  34. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  35. Value of pelvis CT during follow-up of patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00261-016-0869-6↗
  36. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer. Co-author DOI 10.1038/s41598-017-11661-8↗
  37. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Co-author DOI 10.1007/s10637-016-0376-1↗
  38. GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0947↗
  39. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-14-1269↗
  40. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Co-author DOI 10.1158/1535-7163.mct-13-0925↗
  41. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. First author DOI 10.1371/journal.pone.0064566↗

Trials 3

  1. Multicenter Trial of ESK981 in Patients With Select Solid Tumors Principal investigator NCT05988918↗
  2. Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer Principal investigator NCT05411094↗
  3. Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas Principal investigator NCT05926206↗

Grants 1

  1. Targeting the RNA Exosome for Cancer Therapeutics R01CA213214↗

Closest collaborators

The 25 strongest of 181 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Valerie Gunchick · 9 shared papers, 2020–2025 · strength 1.30
  2. Timothy L. Frankel · 7 shared papers, 2020–2026 · strength 1.07
  3. Marina Pasca di Magliano · 8 shared papers, 2016–2026 · strength 1.05
  4. Filip Bednar · 7 shared papers, 2020–2026 · strength 1.02
  5. Eileen S. Carpenter · 7 shared papers, 2020–2026 · strength 1.02
  6. Jiaqi Shi · 7 shared papers, 2018–2026 · strength 1.01
  7. Theodore Steven Lawrence · 6 shared papers, 2019–2025 · strength 0.81
  8. Hari Nathan · 5 shared papers, 2019–2024 · strength 0.62
  9. Mats E. Ljungman · 1 shared grant, 2023 · strength 0.61
  10. Nouri Neamati · 1 shared grant, 2023 · strength 0.61
  11. Thomas Enzler · 3 shared papers, 2021–2024 · strength 0.59
  12. Sunitha Nagrath · 5 shared papers, 2016–2022 · strength 0.57
  13. Costas Andreas Lyssiotis · 4 shared papers, 2020–2026 · strength 0.54
  14. Padma Kadiyala · 3 shared papers, 2024–2026 · strength 0.53
  15. Ahmed M. Elhossiny · 3 shared papers, 2024–2026 · strength 0.53
  16. Upender Manne · 2 shared papers, 2026 · strength 0.53
  17. Ashwini Kumar Esnakula · 2 shared papers, 2026 · strength 0.53
  18. Muhammad Khalid Khan Niazi · 2 shared papers, 2026 · strength 0.53
  19. Abdul Akbar · 2 shared papers, 2026 · strength 0.53
  20. Ashish Manne · 2 shared papers, 2026 · strength 0.53
  21. Susan Tsai · 2 shared papers, 2026 · strength 0.53
  22. Anne M. Noonan · 2 shared papers, 2026 · strength 0.53
  23. Meredith Ann Morgan · 4 shared papers, 2019–2025 · strength 0.52
  24. Samantha B. Kemp · 4 shared papers, 2020–2025 · strength 0.49
  25. Nina G. Steele · 4 shared papers, 2020–2025 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.